RxDoctor Payments Data

Lisa Leazenby

Psychiatric/Mental Health · Twin Falls, IDNPI 1437124658

Payments from drug & device makers

$1,158in general payments, 2019–2025

Across 55 payments — averaging $21.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$311
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$202
  • Neurocrine Biosciences, Inc.$152
  • Alkermes, Inc.$131
  • E.r. Squibb & Sons, L.L.C.$118
  • Johnson & Johnson$115
  • plus $128 from 5 others

What the payments were for

  • Food & beverage$1,06292%
  • Education$968%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,158 in reported general payments places this provider in the 60th percentile of 221 psychiatric/mental health providers in Idaho.

See all psychiatric/mental health providers in Idaho

Medicare billing

Part B allowed, 2024
$9,943
Medicare patients
23
Services billed
128

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega TrinzaPaliperidone Palmitate18$191,570
VraylarCariprazine Hcl93$127,679
CaplytaLumateperone Tosylate32$51,879
LybalviOlanzapine/Samidorphan Malate13$20,066
Aripiprazole80$11,925
TrintellixVortioxetine Hydrobromide22$10,596
LinzessLinaclotide14$7,998
Ziprasidone Hcl45$6,655
Quetiapine Fumarate ErQuetiapine Fumarate32$5,687
Spiriva RespimatTiotropium Bromide11$5,557
Paliperidone ErPaliperidone33$5,015
Doxepin Hcl64$3,217
Celecoxib25$2,681
Buspirone Hcl107$1,983
Ondansetron OdtOndansetron20$1,953

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Trinza$115$191,57018 claims
AbbVieVraylar, Linzess$311$135,677107 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$202$51,87932 claims
Alkermes, Inc.Lybalvi$131$20,06613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 221 psychiatric/mental health providers in Idaho.

Other psychiatric/mental health in Twin Falls

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →